NetScientific PLC discusses FDA fast-track of its portfolio company's cancer treatment



Published
NetScientific PLC chief executive officer Dr Ilian Iliev joins Katie to discuss an immunotherapy drug developed by its portfolio company PDS Biotechnology Corp.

The drug, which will treat recurrent or metastatic head and neck cancer, has been fast-tracked for approval by the Food and Drug Administration (FDA).
Category
Health
Be the first to comment